ASTRAZENECA PLC DelveInsight's, "Metastatic Renal Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Metastatic Renal Cell Carcinoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Metastatic Renal Cell Carcinoma Pipeline Outlook
Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report*
Stay ahead with the most recent pipeline outlook for Metastatic Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Renal Cell Carcinoma Treatment
Metastatic Renal Cell Carcinoma Emerging Drugs Profile*Olaparib:
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.
Explore groundbreaking therapies and clinical trials in the Metastatic Renal Cell Carcinoma Pipeline. Access DelveInsight's detailed report now! @ New Metastatic Renal Cell Carcinoma Drugs
Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration*Inhalation *Inhalation/Intravenous/Oral *Intranasal *Intravenous *Intravenous/ Subcutaneous *NA *Oral *Oral/intranasal/subcutaneous *Parenteral *Subcutaneous
Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as*Antibody *Antisense oligonucleotides *Immunotherapy *Monoclonal antibody *Peptides *Protein *Recombinant protein *Small molecule *Stem Cell *Vaccine
Unveil the future of Metastatic Renal Cell Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report*Coverage- Global *Metastatic Renal Cell Carcinoma Companies-
Get the latest on Metastatic Renal Cell Carcinoma therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Metastatic Renal Cell Carcinoma Companies, Key Products and Unmet Needs
Table of Content*Introduction *Executive Summary *Metastatic Renal Cell Carcinoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Metastatic Renal Cell Carcinoma - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Atezolizumab:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source
